3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Breast Neoplasms
64
Neoplasms
8
Sarcoma
6
Ovarian Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Sarcoma, Ewing
4
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Glioma
4
Carcinoma, Non-Small-Cell Lung
4
Rhabdomyosarcoma
3
Rhabdoid Tumor
3
Prostatic Neoplasms
3
Osteosarcoma
3
Neuroblastoma
3
Melanoma
3
Medulloblastoma
3
Lymphoma
3
Liposarcoma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lung Neoplasms
2
Kidney Neoplasms
2
Interventions
Imatinib Mesylate
27
regorafenib
8
nilotinib
6
Sunitinib
6
pazopanib
3
Temozolomide
3
Paclitaxel
3
Nivolumab
3
Ipilimumab
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
trametinib
2
spartalizumab
2
ripretinib
2
ponatinib
2
envafolimab
2
Specimen Handling
2
Sorafenib
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Laparoscopy
2
Dasatinib
2
Carboplatin
2
CTLA-4 Antigen
2
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
2
vatalanib
1
temsirolimus
1
rubitecan
1
romidepsin
1
perifosine
1
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gastrointestinal Stromal Tumors
×
palbociclib
×
Clear all
NCT01907607
2025-08-24
CYCLIGIST
Institut Bergonié
Phase 2
Completed
29 enrolled
8 charts